Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.

Chris Eijsbouts¹, Yunxuan Jiang², James R Ashenhurst², Julie M Granka², , Steven Pitts², Adam Auton², Noura S Abul-Husn², Alison Chubb², R Ryanne Wu³

¹23andMe Research Institute, 2555 Park Boulevard, Palo Alto, CA, 94306, USA. chris.e@insitro.com.

²23andMe Research Institute, 2555 Park Boulevard, Palo Alto, CA, 94306, USA.

³23andMe Research Institute, 2555 Park Boulevard, Palo Alto, CA, 94306, USA. ryannew@23andme.com.

PubMed DOI

Abstract

We evaluated the effect of CYP2C19 genotype on SSRI response in 114,627 research participants. We graded metabolizer status (0 for ultrarapid metabolizers to 4 for poor metabolizers), and regressed drug response outcomes on these grades. Among participants taking escitalopram or citalopram, slower metabolizers experienced side effects significantly more often than faster metabolizers (OR = 1.04 pe…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.